

Curriculum Vitae

Julien Favresse



Avenue Emile Van Becelaere 19/8, Watermael-Boitsfort

E-mail : julien.favresse@slbo.be

Phone : +32 479 020 590

Birth date : April 5, 1991

Driving licence

CURRENT POSITION

-Specialist in laboratory medicine (EuSpLM), PharmD, Clinique Saint-Luc Bouge, Namur - since October 2019 (Department of Clinical Chemistry – Quality Coordinator).

-PhD Student, UNamur. Promotor: Prof. Jonathan Douxfils; co-promotor: Prof. Jean-Michel Dogné. Title: *“Serological response in COVID-19 patients and in vaccinated subjects”* – since February 2020.

EDUCATION

- 2018 – 2019 **Université Catholique de Louvain**, Woluwe-Saint-Lambert
Master in clinical biology 5th year
Biochemistry (6 months) – Microbiology (6 months)
Summa cum laude
- 2017 – 2018 **Université Catholique de Louvain**, CHU UCL Namur, Yvoir
Master in clinical biology 4th year
Hematology
- 2016 – 2017 **Université Catholique de Louvain**, Woluwe-Saint-Lambert
Master in clinical biology 3rd year
Biochemistry (6 months) – Hematology (6 months)
- 2015 – 2016 **Université Catholique de Louvain**, Woluwe-Saint-Lambert
Master in clinical biology 2nd year
Biochemistry
- 2014 – 2015 **Université Catholique de Louvain**, Woluwe-Saint-Lambert
Master in clinical biology 1st year
Polyvalent. *Magna cum laude*
- 2012 - 2014 **Université Catholique de Louvain**, Woluwe-Saint-Lambert
Master in pharmaceutical sciences. *Magna cum laude*
End of study work: The polymorphism of CYP2D6 in the hormonal treatment of breast cancer with tamoxifen: how to solve the controversy?

2009 - 2012

Université de Namur

Bachelor in Pharmaceutical Sciences. *Magna cum laude*

2008 - 2009

Centre Scolaire Saint Joseph Saint Hubert d'Eghezée

Certificate of secondary education. *Cum laude*

PUBLICATIONS

1. **Favresse J**, Gruson D. Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches.. *Ann Biol Clin (Paris)* 2017, 75:259-267.
2. **Favresse J**, Paridaens H, Pirson N, Maiter D, Gruson D. Massive interference in free T4 and free T3 assays misleading clinical judgment. *Clin Chem Lab Med* 2017; 55: e84-e86.
3. **Favresse J**, Bastin P, Fillée C, Luyckx F, Maiter D, Gruson D. Tracking Macroprolactin: Use of an optimized polyethylene glycol precipitation method more compatible with the requirements and processes of automated core laboratories. *J Appl Lab Med* 2017; 1:661-667.
4. **Favresse J**, Despas N, Gruson D, Vincent MF, Fillée C. Pre-analytics of ammonia: Crioplast® devices as an alternative to icy water. *Clin Chim Acta* 2017, 472:102-103.
5. Bastin P, **Favresse J**, Streel C, Maisin D, Fillée C, Gruson D. Assessment of in vitro stability: a call for harmonization across studies. *Clin Chem Lab Med* 2018,56(5):e121-e124.
6. **Favresse J**, Despas N, Boland L, Gruson D, Laterre PF, Nassogne MC, Vincent MF, Fillée C. Preanalytics of ammonia: stability, transport and temperature of centrifugation. *Clin Chem Lab Med* 2018,23;56:e65-e68.
7. **Favresse J**, van Dievoet MA, De Wolf H, Rodriguez-Villalobos H, Defour JP. Characterization of *Candida* spp. interference on the Sysmex XN-1000 body fluid mode. *Int J Lab Hematol* 2018,40(2):e28-e32.
8. Sottiaux JY, **Favresse J**, Douxfils J, Chatelain B, Jacqmin H, Mullier F. Dosage des D-dimères : variables pré-analytiques, analytiques, post-analytiques et applications cliniques. "La Revue Tribune'k Hémostase" - Vol. 1, no.2 (2019)
9. **Favresse J**, Lardinois B, Chatelain B, Mullier F, Jacqmin H. A reminder of the place of morphology and the H-score in the diagnosis of hemophagocytic lymphohistiocytosis (HLH). *Clin Case Report* 2018,6(3):527-528.
10. **Favresse J**, Lardinois B, Nassogne MC, Preumont V, Maiter D, Gruson D. Anti-streptavidin antibodies mimicking heterophilic antibodies in thyroid function tests. *Clin Chem Lab Med* 2018,27;56(7):e160-e163.
11. **Favresse J**, Lardinois B, Chatelain B, Jacqmin H, Mullier F. Evaluation of the fully automated HemosIL® Acustar ADAMTS13 Activity assay. *Thromb Haemost* 2018,118(5):942-944.
12. **Favresse J**, Lardinois B, Sabor L, Devalet B, Vandepapelier J, Braibant M, Lessire S, Chatelain B, Jacqmin H, Douxfils J, Mullier F. Evaluation of the DOAC-Stop® procedure to overcome the effect of DOACs on several thrombophilia screening tests. *TH Open* 2018,02(02):e202-e209.
13. **Favresse J**, Burlacu MA, Maiter D, Gruson D. Interferences with thyroid function immunoassays: clinical implications and detection algorithm. *Endocr Rev* 2018,1;39(5):830-850
14. **Favresse J**, Lippi G, Ten Cate H, Mullier F. D-dimers: preanalytics, analytics, postanalytics, and clinical interests. *Critical Reviews in Clinical Laboratory Sciences* 2018, 55(8):548-577
15. Dincq AS, Lessire S, Pirard G, Siriez R, Guldenpfennig M, Baudar J, **Favresse J**, Douxfils J, Mullier F. Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. *Int J Lab Hematol* 2018, 40(6):e105-e108.
16. Exner T, **Favresse J**, Lessire S, Douxfils J, Mullier F. Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent. *Thromb Res.* 2019 Jul;179:69-72.

17. **Favresse J**, Hardy M, van Dievoet MA, Sennesael AL, Douxfils J, Samama CM, Vornicu O, Dincq AS, Lessire S, Mullier F. Andexanet alfa for the reversal of factor Xa inhibitors. *Expert Opin Biol Ther.* 2019 May;19(5):387-397.
18. Bayart JL, **Favresse J**, Melnik E, Lardinois B, Fillée C, Maiter D, Gruson D. Erroneous thyroid and steroid hormones profile due to anti-streptavidin antibodies. *Clin Chem Lab Med.* 2019 ePub ahead of print.
19. **Favresse J**, Stoefs A, Bayart JL, Burlacu MC, Maisin D, Maiter D, Gruson D. A challenging case of falsely elevated free thyroid hormones. *The Journal of Applied Laboratory Medicine* 2020, Epub ahead of print.
20. Soleimani R, Brousmiche K, **Favresse J**, Haufroid V, Gruson D, Hantson P, Wallemacq P. Intentional acetylsalicylic acid acute intoxication and its clinical management. *Clinical Case Report* 2020 (Epub ahead of print).
21. Soleimani R, **Favresse J**, Roy T, Gruson D, Fillée C. Macro vitamin B12: an underestimated threat. *Clin Chem Lab Med.* 2020 Feb 25;58(3):408-415.
22. Sottiaux JY, **Favresse J**, Chevalier C, Chatelain B, Jacqmin H, Mullier F. Evaluation of a hereditary spherocytosis screening algorithm by automated blood count using reticulocytes and erythrocytic parameters on the Sysmex XN-series. *Int J Lab Hematol.* 2020 Apr;42(2):e88-e91.
23. **Favresse J**, Fervaille C, Wuestenberghs F, Chatelain B, Mullier F, Jacqmin H. Utility of the XN-1000 research mode for leukocytes counting in ascitic and pleural fluids. *Int J Lab Hematol.* 2019 Nov 25. doi: 10.1111/ijlh.13128 (Epub ahead of print).
24. Bayart JL, **Favresse J**, Stoefs A, Closset M, Roy T, Fillée C, Rodriguez-Villalobos H, Kabamba-Mukadi B, Gruson D. Biotin interferences: Have we neglected the impact on serological markers? *Clin Chim Acta.* 2020 Apr;503:107-112.
25. **Favresse J**, Bayart JL, Stoefs A, Gheldof D, Douxfils J, Dogné JM, Gruson D. Neutralization of biotin interference: preliminary evaluation of the VeraTest Biotin™, VeraPrep Biotin™ and BioT-Filter®. *Clin Chem Lab Med.* 2020 (Epub ahead of print).
26. **Favresse J**, Boland L, Schellen M, Fervaille C, Wuestenberghs F, Camboni A, Chatelain B, Mullier F, Defour JP, Jacqmin H. Two-site evaluation of a new workflow for the detection of malignant cells on the Sysmex XN-1000 body fluid analyzer. *Int J Lab Hematol.* 2020 (Epub ahead of print).
27. **Favresse J**, Gruson D, Gheldof D. Comment on "High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: Implications for individuals with biotin-responsive inherited metabolic disorders". *Mol Genet Metab Rep.* 2019 Aug 22;21:100506.
28. SIBioC young scientists Laboratory Medicine (including **Favresse J**): specialists of tomorrow. July 2019 *Biochimica Clinica*. DOI: 10.19186/BC_2019.039.
29. Mzougui S, **Favresse J**, Soleimani R, Fillée C, Gruson D. Biotin interference: evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing. *Clin Chem Lab Med* 2020 Nov 26;58(12):2037-2045.
30. **Favresse J**, Eucher C, Elsen M, Tré-Hardy M, Dogné JM, Douxfils J. Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies. *Clin Chem.* 2020 Aug 1;66(8):1104-1106. doi: 10.1093/clinchem/hvaa131.
31. **Favresse J**, Eucher C, Elsen M, Graux C, Goebels P, Laffineur K, Nicolas JB, Dogné JM, Douxfils J. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. *Br J Haematol.* 2020 Aug;190(4):e187-e189.
32. **Favresse J**, Eucher C, Elsen M, Laffineur K, Dogné JM, Douxfils J. Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. *Clin Chem Lab Med.* 2020 Sep 25;58(10):e193-e196. doi: 10.1515/cclm-2020-0962.

33. Tré-Hardy M, Wilmet A, Beukinga I, **Favresse J**, Dogné JM, Douxfils J, Blairon L. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. *J Med Virol*. 2021 Feb;93(2):803-811. doi: 10.1002/jmv.26303.
34. **Favresse J**, Cadrobbi J, Eucher C, Laffineur K, Rosseels C, Pieters D, Elsen M, Gras J. Non-reproducible cardiac troponin results occurring with a particular reagent lot. *Clin Chem Lab Med*. 2020 Jul 20:/j/cclm.ahead-of-print/cclm-2020-0562/cclm-2020-0562.xml.
35. Mairesse A, **Favresse J**, Eucher C, Elsen M, Tré-Hardy M, Haventith C, Gruson D, Dogné JM, Douxfils J, Göbbels P. High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. *Clin Biochem*. 2020 Dec;86:23-27. doi: 10.1016/j.clinbiochem.2020.08.009
36. Mairesse A, Wauthier L, Courcelles L, Luyten U, Burlacu MC, Maisin D, **Favresse J**, van Dievoet MA, Gruson D. Biological variation and analytical goals of four thyroid function biomarkers in healthy European volunteers. *Clin Endocrinol (Oxf)*. 2020 Oct 26. doi: 10.1111/cen.14356.
37. **Favresse J**, Cadrobbi J, Eucher C, Elsen M, Laffineur K, Dogné JM, Douxfils J. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. *J Med Virol*. 2020 Nov 17;10.1002/jmv.26669.
38. Gillot C, Douxfils J, Cadrobbi J, Laffineur K, Dogné JM, Elsen M, Eucher C, Melchionda S, Modaffarri É, Tré-Hardy M, **Favresse J**. An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. *J Clin Med*. 2020 Nov 21;9(11):3752. doi: 10.3390/jcm9113752.
39. **Favresse J**, Bayart JL, Burlacu MC, Maiter D, Dogné JM, Douxfils J, Gruson D. Usefulness of a Non-Streptavidin Bead Technology to Overcome Biotin Interference: Proof of Principle with 25-OH Vitamin D, TSH, and FT4. *J Appl Lab Med*. 2020 Dec 31;jfaa203
40. **Favresse J**, Brauner J, Bodart N, Vigneron A, Roisin, S, Mechionda S, Douxfils J, Ocmant J. An original multiplex method to assess five different SARS-CoV-2 antibodies. *Epub ahead of print*. <https://doi.org/10.1515/cclm-2020-1652>.
41. **Favresse J**, Elsen M, Eucher C, Laffineur K, Van Eeckhout S, Nicolas JB, Constant Gillot, Dogné JM, Douxfils J. Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. *Epub ahead of print*. <https://doi.org/10.1515/cclm-2020-1736>.
42. Haguët H, Douxfils J, Eucher C, Elsen M, Cadrobbi J, Tré-Hardy M Dogné JM, **Favresse J**. Clinical performance of the Panbio assay for the detection of SARS-CoV-2 IgM and IgG in COVID-19 patients. *Journal of Medical Virology*. <https://doi.org/10.1002/jmv.26884>.
43. Didembourg M, Douxfils J, Mullier F, Hardy M, **Favresse J**, Morimont L. Influence of C-reactive protein on thrombin generation assay. *Clinical Chemistry and Laboratory Medicine*. 10.1515/cclm-2020-1686.
44. Lardinois B, Favresse J, Chatelain C, Lippi G, Mullier F. Pseudothrombocytopenia—A Review on Causes, Occurrence and Clinical Implications. *Journal of Clinical Medicine*. doi.org/10.3390/jcm10040594.
45. **Favresse J**, Gillot C, Oliveira M, Cadrobbi J, Elsen J, Eucher C, Laffineur K, Rosseels C, Van Eeckhout S, Nicolas JB, Morimont L, Dogné JB, Douxfils J. Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. *Journal of Clinical Medicine*. <https://doi.org/10.3390/jcm10020265>.

46. **Favresse J**, Bayart JL, Gruson D, Bernardini S, Clerico A, Perrone M. The underestimated issue of non-reproducible cardiac troponin I and T results: case series and systematic review of the literature. *Clinical Chemistry and Laboratory Medicine*. <https://doi.org/10.1515/cclm-2020-1564>.
47. Wauthier L, Di Chiaro L, **Favresse J**. Sigma Metrics in Laboratory Medicine: A Call for Harmonization. *Clinica Chimica Acta*. 10.1016/j.cca.2022.05.012
48. Lippi G, **Favresse J**, Gromiha M, Sorelle J, Plebani M, Henry BM. Ad interim recommendations for diagnosing SARS-CoV-2 infection by the IFCC SARS-CoV-2 variants working group. 10.1515/cclm-2022-0345.
49. Gillot C, **Favresse J**, Maloteau V, Dogné JM, Douxfils J. Identification of SARS-CoV-2 Neutralizing Antibody with Pseudotyped Virus-based Test on HEK-293T hACE2 Cells. *Bio-Protocol*. 10.21769/BioProtoc.4377.
50. **Favresse J**, Dogné JM, Douxfils J. Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster. *Clinical Chemistry and Laboratory Medicine*. 10.1515/cclm-2022-0323.
51. Bayart JL, Degosserie J, **Favresse J**, Gillot C, Didembourg M, Phanio D, Verbelen G, Maschietto C, Mullier F, Dogné JM, Douxfils J. Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant. *Viruses*. 10.3390/v14040654.
52. Wauthier L, Plebani M, **Favresse J**. Interferences in immunoassays: review and practical algorithm. *Clinical Chemistry and Laboratory Medicine*. 10.1515/cclm-2021-1288.
53. Nevrumont A, Deltombe M, **Favresse J**, Guillaume L, Chapelle V, Tweenbold R, Gruson D. Interferences with cardiac biomarker assays: understanding the clinical impact. *European Heart Journal*. 10.1093/eurheartj/ehab924.
54. **Favresse J** and Delanghe J. High-resolution capillary electrophoresis for the determination of carbamylated albumin. *Clinical Chemistry and Laboratory Medicine*. 2021. 10.1515/cclm-2021-0926.
55. **Favresse J** and Douxfils J. Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination. *Journal of Infection*. 2021. 10.1016/j.jinf.2021.07.001.
56. **Favresse J**, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, Roy T, Wieers G, Laurent C, Dogne JM, Closset M, Douxfils J. Antibody titres decline 3-month post-vaccination with BNT162b2. *Emerging Microbes and Infections*. 2021. 10.1080/22221751.2021.1953403.
57. **Favresse J** and Douxfils J. Evaluations of SARS-CoV-2 Serological Assay Performance Need Inclusion of Long-Term Samples. *Journal of Clinical Microbiology*. 2021. 10.1128/JCM.00487-21.
58. **Favresse J**, Gillot C, Douxfils J. COVID-19 patients and BNT162b2 doses. *Encyclopedia.pub/13380*.
59. Douxfils J, **Favresse J**, Dogne JM, Lecompte T, Susen S, Cordonnier C, Lebreton A, Gosselin R, Sie P, Pernod G, Gruel Y, Nguyen P, Vayne, Mullier F. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. *Thrombosis Research*. 2021. 10.1016/j.thromres.2021.05.010.
60. **Favresse J**, Bayart JL, David C, Gillot C, Wieers G, Roussel G, Sondag G, Elsen M, Eucher C, Dogne JM, Douxfils J. Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity. *medRxiv pre-print*. 2021. 10.1101/2021.11.18.21266478.
61. Gillot C, **Favresse J**, Mullier F, Lecompte T, Dogne JM, Douxfils J. NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. *Frontiers in Pharmacology*. 2021. 10.3389/fphar.2021.708302.

62. Douxfils J, Gillot C, Mullier F, **Favresse J**. Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ. *Journal of Infection*. 2021. 10.1016/j.jinf.2021.08.023.
63. Bayart JL, Douxfils J, Gillot C, David C, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, Roy T, Gerin V, Wieers G, Laurent C, Closset M, Dogne JM, **Favresse J**. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. *Vaccines*. 2021. 10.3390/vaccines9101092.
64. **Favresse J**, Gillot C, Douxfils J. Reply to Schulte-Pelkum, J. Comment on "Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. *Microorganisms* 2021, 9, 556". *Microorganisms*. 2021. 10.3390/microorganisms9091849.
65. Douxfils J, Gillot C, De Gottal E, Vandervinne S, Bayart JL, Dogne JM, **Favresse J**. Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature. *Vaccines*. 2021.10.3390/vaccines9080907.
66. Douxfils J, Wayne C, Pouplard C, Lecompte T, **Favresse J**, Potier F, Gasser E, Mathieux V, Dogne JM, Gruel Y, Rollin J, Mullier F. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rationale for monitoring immunoglobulin G levels. *Haematologia*. 2021. 10.3324/haematol.2021.279509.
67. Gillot C, **Favresse J**, Maloteau V, Dogne JM, Douxfils J. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects. *Viruses*. 2021. 10.3390/v13112329.
68. **Favresse J**, Lenga Y, Gras J. Evaluation of a Capillary Electrophoresis System for the Separation of Proteins. *Journal of Applied Laboratory Medicine*. 2021. 10.1093/jalm/jfab044.
69. Bayart JL, Morimont L, Closset M, Wieers G, Roy T, Gerin V, Elsen M, Eucher C, Van Eeckhoudt S, Ausselet N, David N, Mullier F, Dogne JM, **Favresse J**, Douxfils J. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. *Microorganisms*. 2021. 10.3390/microorganisms9061340.
70. **Favresse J**, Bayart JL, David C, Didembourg M, Gillot C, Dogné JM, Douxfils J. Spike vs. nucleocapsid serum antigens for COVID-19 diagnosis and severity assessment. *Clinical Chemistry and Laboratory Medicine*. 10.1515/cclm-2021-1244.
71. **Favresse J**, Bayart JL, David C, Dogné JM, Douxfils J. Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity. *Journal of Infection*. 10.1016/j.jinf.2022.01.023.
72. **Favresse J**, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S, David C, Morimont L, Dogné JM, Douxfils J. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. *Viruses*. 10.3390/v13071364.

PRESENTATIONS CONGRESS

1. CORATA Belge. 29 September 2016, Strasbourg, Recherche de la Macroprolactine: état des lieux en 2016.

2. Soirée AABC, 26 May 2017, Brussels, Interferences in immunoassays of thyroid function, clinical implications and proposed detection algorithm.
3. Namur Thrombosis and Haemostasis Center (NTHC), 29 March 2018, Namur. Bayesian strategy in long-term IQC results management.
4. International Society for Laboratory Hematology (ISLH), 11 May 2018, Brussels, Evaluation of the DOAC-Stop[®] procedure to overcome the effect of DOACs on several thrombophilia screening tests (young travel award received).
5. Sysmex Meeting Club, 24 May 2018, Namur, Automated analysis of body fluids: interest of reflex testing rules?
6. International Society on Thrombosis and Haemostasis (ISTH), 18 July 2018, Dublin, LAC Testing during DOAC: Neutralizing the Culprit?
7. CORATA Belge, 21 September 2018, Rouens, Dosage des D-dimères : état de l'art en 2018.
8. 2° Convegno GDS SIBioC Young Scientists, 3 December 2018, Rome, Italy. The importance of communication between physicians and the lab: the case of thyroid interferences.
9. Sysmex Academy, Namur, The search of malignant cells in body fluids, 24 October 2019.
10. Werfen user day, Charleroi, The use of D-dimer, 26 October 2019.
11. BioMérieux Maghreb, June 2022, Interférences sur le dosage de la troponine: focus sur les résultats non-reproductibles et implications cliniques.
12. Conférence IFCC-Snibe 18/10/2021 – “SARS-CoV-2 antibody persistence: the importance of the assay target”.
13. Conférence YHLO 07/06/2021 – “Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2”.
14. GLEM du 18/11/2021 – “Kinetics of SARS-CoV-2 antibodies and detection of SARS-CoV-2 antigen in blood”.
15. Conférence SSPF – interprétation prise de sang à l'officine (formation en journée).
 - Liège, le 23/09/2021
 - Namur, le 05/10/2021
 - Mons, le 21/10/2021
 - Luxembourg, le 16/11/2021
 - Louvain-la-Neuve, le 30/11/2021
 - Nivelles, le 07/12/2021

REVIEWER

1. *Clinical Chemistry and Laboratory Medicine*
2. *International Journal of Laboratory Hematology*
3. *Clinical Biochemistry*
4. *Clinica Chimica Acta*
5. *Journal of Applied Laboratory Medicine*
6. *Clinical Chemistry*
7. *Thrombosis Journal*
8. *Microorganisms*
9. *Diagnostics*
10. ...

SCIENTIFIC ORGANISATIONS

1. *Editorial Board Member of Clinical Chemistry and Laboratory Medicine, since April 2021.*
2. *Editorial Board Member of Clinica Chimica Acta, Since June 2022.*
3. *AACC Trainer Member, since June 2017.*
4. *EFLM Member since December 2020.*
5. *RBSLM Trainee Member, since February 2019.*
6. *Past vice-President of Association des Assistants en Biologie Clinique (AABC).*

LANGUAGE

	Writing	Speaking	Reading
French	Mother tongue	Mother tongue	Mother tongue
English	C1	C1	C2
Dutch	B2	B2	B2

OTHERS

- Literature, cinema, running, squash, cooking, travelling

